Ignite Creation Date:
2024-05-05 @ 10:56 PM
Last Modification Date:
2024-10-26 @ 10:25 AM
Study NCT ID:
NCT01210274
Status:
UNKNOWN
Last Update Posted:
2017-08-23
First Post:
2010-09-27
Brief Title:
Characterization of the Mechanisms of Resistance to Azacitidine
Sponsor:
Centre Hospitalier Universitaire de Nice
Organization:
Centre Hospitalier Universitaire de Nice
Study Overview
Official Title:
Characterization of the Mechanisms of Action of Resistance to Azacitidine in High-risk Myelodysplastic Syndromes and Acute Myeloid Leukemia With Multilineage Dysplasia
Status:
UNKNOWN
Status Verified Date:
2017-08
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Myelodysplastic syndromes MDS are frequent diseases in elderly patients median age 71 years IPSS classification defines low risk Low and Intermediate 1 and high risk Intermediate 2 and High MDS High-risk MDS MDS-HR have a high risk of transformation into acute leukemia with multilineage dysplasia AML-DML The success of Azacitidine has been mainly achieved through a rigorous empirical and clinical research but the molecular mechanisms by which this molecule exerts its effects remain poorly characterized The primary mode of action of Azacytidine is through DNA demethylation and integration in to mRNA that favor traduction inhibition The impact of this molecule on various cell death programs involved in the elimination of leukemic cells apoptosis and autophagy is currently poorly known
The research program and clinical studies we proposed focus on two major aspects
- Main objective Molecular mechanism of action and resistance to Azacitidine Role of apoptosis versus autophagy
- Secondary Objective Reversion of Azacytidine resistance using different drugs targeting apoptosis andor autophagy Our laboratory has identified new molecules to selectively induce different types of cell death apoptosis or autophagy
The research program and clinical studies we proposed focus on two major aspects
- Main objective Molecular mechanism of action and resistance to Azacitidine Role of apoptosis versus autophagy
- Secondary Objective Reversion of Azacytidine resistance using different drugs targeting apoptosis andor autophagy Our laboratory has identified new molecules to selectively induce different types of cell death apoptosis or autophagy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None